IGM Biosciences to Present at the Stifel 2024 Virtual Immunology and Inflammation Summit
September 10 2024 - 4:05PM
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage
biotechnology company creating and developing engineered IgM
antibodies, today announced that Fred Schwarzer, Chief Executive
Officer, and Mary Beth Harler, M.D., Head, Research &
Autoimmunity, will participate in a fireside chat at the Stifel
2024 Virtual Immunology and Inflammation Summit on Tuesday,
September 17, 2024, at 9:00 a.m. EDT.
A live webcast of the event will be available on the “Events and
Presentations” page in the “Investors” section of the Company’s
website at
https://investor.igmbio.com/news-and-events/events-and-presentations.
A replay of the webcast will be archived on the Company’s website
for 90 days following the presentation.
About IGM Biosciences, Inc.IGM
Biosciences is a clinical-stage biotechnology company
committed to developing and delivering a new class of medicines to
treat patients with cancer and autoimmune and inflammatory
diseases. IGM’s pipeline of clinical and preclinical assets is
based on the IgM antibody, which has 10 binding sites compared to
conventional IgG antibodies with only 2 binding sites. IGM also has
an exclusive worldwide collaboration agreement with Sanofi to
create, develop, manufacture, and commercialize IgM antibody
agonists against immunology and inflammation targets. For more
information, please visit www.igmbio.com.
Contact:Argot PartnersDavid
Pitts212-600-1902igmbio@argotpartners.com
IGM Biosciences (NASDAQ:IGMS)
Historical Stock Chart
From Aug 2024 to Sep 2024
IGM Biosciences (NASDAQ:IGMS)
Historical Stock Chart
From Sep 2023 to Sep 2024